Monopar Therapeutics (MNPR) Long-Term Investments (2022 - 2026)
Monopar Therapeutics (MNPR) posted Long-Term Investments of $78.6 million for Q4 2025, up 391.08% sequentially from $16.0 million in Q3 2025, and up 445.75% YoY from $14.4 million in Q4 2024.
Monopar Therapeutics (MNPR) Long-Term Investments (2022 - 2026) Analysis & Trends
Monopar Therapeutics has reported Long-Term Investments for 4 years, with the latest figure at $78.6 million in Q4 2025.
- Quarterly Long-Term Investments rose 445.75% year-over-year to $78.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $78.6 million (up 445.75% YoY) and the FY2025 annual result came in at $78.6 million, up 445.75% from the prior year.
- Long-Term Investments climbed to $78.6 million in Q4 2025 per MNPR's latest filing, from $16.0 million in the prior quarter.
- Over five years, Long-Term Investments peaked at $78.6 million in Q4 2025 and troughed at $985730.0 in Q1 2024.
- A 4-year average of $14.2 million and a median of $6.0 million in 2023 frame the typical range for Long-Term Investments.
- The sharpest annual moves came in 2024 and 2025: Long-Term Investments plunged 83.43% in 2024, then surged 1405.61% in 2025.
- Over 4 years, Long-Term Investments stood at $4.9 million in 2022, then slumped by 39.61% to $3.0 million in 2023, then surged by 383.17% to $14.4 million in 2024, then jumped by 445.75% to $78.6 million in 2025.
- According to Business Quant data, Long-Term Investments over the past three periods registered $78.6 million, $16.0 million, and $13.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Monopar Therapeutics | 965.64 Mn | 912.88 Mn | - | 81.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 81.54 Mn |
| Dec 31, 2025 | 78.57 Mn |
| Sep 30, 2025 | 16.00 Mn |
| Jun 30, 2025 | 13.75 Mn |
| Mar 31, 2025 | 14.84 Mn |
| Dec 31, 2024 | 14.40 Mn |
| Jun 30, 2024 | 998,840.00 |
| Mar 31, 2024 | 985,730.00 |
| Sep 30, 2023 | 2.98 Mn |
| Jun 30, 2023 | 2.98 Mn |
| Mar 31, 2023 | 5.95 Mn |
| Dec 31, 2022 | 4.93 Mn |